Selective intracellular effects leading to immunogenic cell death (ICD) in prostate cancer cell models


NEW YORK, March 10, 2022 /PRNewswire/ — Phosphlatin Therapeutics Inc., a clinical-stage pharmaceutical company focused on oncology therapeutics, announced today that the American Academy of Cancer Research (AACR) will host an in-person poster presentation on its lead candidate PT-112 and how it selectively induces severe mitochondrial stress. immunogenic cell death in human prostate cancer cell lines. The presentation will take place on AACR Annual Meeting 2022 takes place on April 8-13, 2022 in New Orleans.

(PRNews photo/Phosphlatin Therapeutics LLC)

The work to be presented was produced by the company as part of a research collaboration with the Anel Lab of the University of Zaragoza, Spain. Characterizing the intracellular pathways leading to ICD and the adaptive immune response is an important research goal for the Company and a peer-reviewed manuscript is in preparation.

Presentation title: “PT-112 Induces Severe Mitochondrial Stress and Immunogenic Cell Death in Human Prostate Cancer Cell Lines”
lead author: R. Soler, University of Zaragoza/Aragón Health Research Institute, Biochemistry and Molecular and Cellular Biology, Zaragoza, Spain
Session category: Experimental and molecular therapeutics
Meeting: Mechanisms of action of drugs 3
Session Date/Time: Monday April 11, 2022 onwards 9:00 am12:30 PM CST
Location: New Orleans Convention Center, Exhibit Halls DH, Poster Section 24
Poster number: 5

The presentation will be available both in person and online procedure of AACR by the conference website.

For more information on Phosphlatin clinical trials, visit the website at

About PT-112

PT-112 is the first small molecule conjugate of pyrophosphate in oncology and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD) through the release of damage-associated molecular patterns (DAMPs) that bind to dendritic cells and lead to the downstream recruitment of Immune effector cells in the tumor microenvironment. PT-112 may be the best-in-class inducer of this immunological form of cancer cell death. In addition, PT-112 exhibits a property known as osteotropism, or the drug’s propensity to reach its highest concentrations in certain areas of bone, making it a candidate for treating patients with cancers that originate from have in the bone or metastasize there. The first human study of PT-112 showed an attractive safety profile and evidence of long-lasting responses in heavily pretreated patients and was recognized as “Best Poster” in the Developmental Therapeutics category at the 2018 ESMO Annual Meeting. The combination phase 1b Dose escalation study of PT-112 with the PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress. The Phase 1 study presented at ASH in patients with relapsed or refractory multiple myeloma is the third completed Phase 1 study of PT-112. Phase 2 monotherapy development in mCRPC is ongoing and the PD-L1 combination study is ongoing in a dose-confirmation cohort of non-small cell lung cancer (NSCLC) patients and will soon enter the Phase 2 proof-of-concept study Thymic epithelial tumors include, as part of the company’s collaboration with the NCI.

About phosphate therapeutics

Phosphaplatin Therapeutics Inc. is a privately held clinical-stage pharmaceutical company with the exclusive worldwide license to Phosphaplatin, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with associated with chemotherapeutic treatments. The Company’s lead candidate, PT-112, is a novel investigational chemical in clinical development with a unique combination of properties including immunogenic cell death and osteotropism. Clinical data generated from three Phase 1 studies to date have demonstrated single agent anticancer efficacy and an attractive safety profile, and three Phase 2 studies of PT-112 are ongoing. The company’s research and development work was funded by private investors and family investment offices The United States, Europe and Asiaalong with a sublicense agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical trial of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operates as EMD Serono in the US and Canada) and has an active research and development agreement (CRADA) with NCI to conduct a Phase 2 study using PT-112 in thymic epithelial tumors.


phosphate therapeutics
Taylor Young
Senior Director of Strategic Development
Tel: +1 646 974 6456
Email: [email protected]

ICR Westwicke
Stephanie Carrington
Tel: +1 646 277 1282
Email: [email protected]

Markus Corbae
Tel: +1 203 682 8288
Email: [email protected]



View the original content to download multimedia: cell-death-icd-in-prostate-cancer-cell-models-301499763.html

SOURCE Phosphlatin therapeutics


Comments are closed.